JUN 09, 2020 8:31 AM PDT

Psychedelic DMT Improves Wellbeing in 89% of People

WRITTEN BY: Annie Lennon

DMT is a powerful psychedelic drug known to produce visions involving 'other beings' like elves, aliens, and deities. Researchers from Johns Hopkins School of Medicine have surveyed over 2,500 people who have taken the drug to understand the impact these experiences had on them. 

Most of the participants had used DMT (N, N-Dimethyltryptamine) around a dozen times. The study excluded people who consumed ayahuasca and those whose DMT experiences may have been influenced by other drugs taken at the same time. 

In the end, the researchers found that 99% of those who encountered other beings during their DMT experiences had an emotional response. While 59% of participants felt love, 65% felt joy, and 63% felt trust. A minority felt negative emotions, including sadness (13%) and disgust (4%). 

At the same time, 81% of respondents said that their encounters felt 'more real than reality.' Around 75% reported believing that the beings they encountered were real, but existed in another dimension or reality, while only 9% thought the experiences existed 'completely within themselves.' 

"Additionally, approximately one-third (36%) of respondents reported that before the encounter their belief system included a belief in ultimate reality, higher power, God, or universal divinity, but a significantly larger percentage (58%) of respondents reported this belief system after the encounter." say the researchers. 

Meanwhile, 60% of the survey respondents thought that DMT "produced a desirable alteration in their conception of reality, whereas only 1% indicated an undesirable alteration in their conception of reality."

Adding to this, 89% of participants said the encounters led to lasting improvements in their wellbeing and life satisfaction. As such, the researchers think that the drug may hold promise as a therapy for people with mood and behavioral problems such as depression and addiction, in years to come. 

Although an observational study not conducted under lab conditions, the researchers hope that these early findings may open further research avenues for the drug.



Sources: Big Think, New Atlas

About the Author
Other
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
DEC 12, 2022
Drug Discovery & Development
Accelerated Removal of the Previous Approval
Accelerated Removal of the Previous Approval
The FDA’s accelerated approval process had attracted criticism from researchers, FDA advisory committee members, a ...
JAN 03, 2023
Clinical & Molecular DX
Antimicrobial Peptides: The Solution to Antimicrobial Resistance?
Antimicrobial Peptides: The Solution to Antimicrobial Resistance?
According to the World Health Organization, antimicrobial resistance is among the top ten global health threats facing h ...
FEB 03, 2023
Drug Discovery & Development
Tzield: Newest Type 1 Diabetes Drug
Tzield: Newest Type 1 Diabetes Drug
Type 1 Diabetes (T1D) is a autoimmune genetic disease that results in a person’s pancreas not making enough insuli ...
JAN 05, 2023
Health & Medicine
Potential Over-the-Counter Access to Naloxone- a life saving drug
Potential Over-the-Counter Access to Naloxone- a life saving drug
Naloxone is a powerful FDA-approved opioid antagonist that works to reverse life-threatening opioid overdoses. Sinc ...
JAN 04, 2023
Clinical & Molecular DX
Dual-Action Cancer Vaccine Targets Brain Tumors Directly
Dual-Action Cancer Vaccine Targets Brain Tumors Directly
Scientists have developed a new, targeted strategy to eliminate brain tumors and prevent future recurrences of brain can ...
JAN 18, 2023
Technology
Artificial pancreas for type 2 diabetes management
Artificial pancreas for type 2 diabetes management
Type 2 diabetes is an increasingly common condition around the globe, affecting over 400 million people. In type 2 diabe ...
Loading Comments...